Latest Ratios: P/E Ratio -0.2x · EV/EBITDA N/A · ROE -141.7%. (2021–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $8M | $7M | $5M | $4M | — | — |
| Enterprise Value | $7M | $6M | $5M | $4M | — | — |
| P/E Ratio → | -0.22 | — | — | — | — | — |
| P/S Ratio | 17.11 | 16.34 | 7.78 | 6.09 | — | — |
| P/B Ratio | 0.30 | 0.49 | 0.34 | 5.75 | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | 13.76 | 8.03 | 5.26 | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | 54.9% | 54.9% | 61.7% | 59.0% | 54.3% | — |
| Operating Margin | -4200.5% | -4200.5% | -1294.4% | -1260.3% | -22279.7% | — |
| Net Profit Margin | -4526.9% | -4526.9% | -1413.6% | -1259.4% | -22352.1% | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | -141.7% | -141.7% | -118.3% | -1326.7% | -669.0% | — |
| ROA | -131.2% | -131.2% | -106.0% | -897.0% | -389.5% | -78.5% |
| ROIC | -102.2% | -102.2% | -83.8% | -3083.5% | -1051.8% | — |
| ROCE | -131.5% | -131.5% | -107.8% | -1165.2% | -548.7% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.02 | 0.17 | 0.57 | — |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.08 | 0.01 | -0.79 | -0.54 | — |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | -198.43 | -198.43 | -634.60 | — | -307.68 | -96.80 |
Net cash position: cash ($1M) exceeds total debt ($307823)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 1.74 | 1.74 | 0.05 | 3.88 | 2.67 | 0.57 |
| Quick Ratio | 1.74 | 1.74 | 0.05 | 3.79 | 2.67 | 0.57 |
| Cash Ratio | 1.67 | 1.67 | 0.04 | 3.50 | 2.62 | 0.57 |
| Asset Turnover | — | 0.03 | 0.04 | 0.70 | 0.01 | — |
| Inventory Turnover | — | — | — | 16.21 | — | — |
| Days Sales Outstanding | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | 16.7% | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 16.7% | 0.0% | — | — |
| Shares Outstanding | — | $10M | $2M | $1M | $1M | $997666 |
Includes 30+ ratios · 5 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MGRX stock.
Mangoceuticals, Inc.'s current P/E ratio is -0.2x. This places it at the 50th percentile of its historical range.
Mangoceuticals, Inc.'s return on equity (ROE) is -141.7%. The historical average is -130.0%.
Based on historical data, Mangoceuticals, Inc. is trading at a P/E of -0.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Mangoceuticals, Inc. has 54.9% gross margin and -4200.5% operating margin.
Key Metrics
Top Statement Risk
Existential liquidity and solvency
Metrics are mathematically derived from official filings.
Speculative Multiples Defy Operational Reality
According to current market data, MGRX trades at a price-to-sales ratio of 8.10, a valuation that appears disconnected from the company's 25.96% year-over-year revenue contraction and the absence of a clear path toward positive earnings or sustainable cash flow generation in the near term.
The current P/S multiple suggests that investors may be pricing in a turnaround or acquisition potential that is not supported by the underlying financial performance. Given the lack of positive EBITDA or FCF, traditional valuation metrics like P/E or EV/EBITDA are effectively meaningless, leaving the stock to trade on speculative sentiment rather than fundamental value.
Capital Destruction Outpaces Value Creation
Based on reported figures, MGRX has consistently generated negative ROIC, with recent quarterly data showing a return of -17.0%, indicating that the company is actively destroying shareholder capital rather than compounding it through its current direct-to-consumer telemedicine business model and operational structure.
The persistent negative ROIC reflects an inability to generate returns that exceed the cost of capital, largely driven by the massive operating losses relative to the asset base. This trend suggests that the company's investments in platform development and marketing have failed to produce a competitive advantage or a scalable, profitable return on invested capital.
Working Capital Management Remains Erratic
As reported in financial statements, the company's efficiency metrics, including a highly volatile cash conversion cycle and extremely high days payable outstanding, suggest significant friction in managing supplier relationships and liquidity, which complicates the company's ability to maintain a stable operational rhythm in the competitive telehealth space.
The extreme DPO figures, which have reached over 2,900 days in past periods, imply that the company may be relying on extended payment terms with vendors to preserve cash, a strategy that is likely unsustainable. This reliance on vendor financing highlights a structural weakness in working capital efficiency that leaves the company vulnerable to supply chain disruptions.
Liquidity Position Nearing Critical Threshold
According to recent quarterly filings, the current ratio has deteriorated to 0.29, a level that indicates severe stress and suggests that the company may lack the liquid assets necessary to cover its short-term liabilities without immediate and potentially dilutive external financing or a significant operational pivot.
The rapid decline in the current ratio from 1.74 in 2025Q4 to 0.29 in 2026Q1 underscores a precarious liquidity position that warrants close monitoring by investors. This trend suggests that the company's cash reserves are being depleted at an alarming rate, leaving little margin for error in managing its ongoing operating expenses.
Misapplication of Growth-Stage Valuation Metrics
Investors frequently misapply standard growth-stage valuation multiples to MGRX, failing to recognize that the company's revenue contraction and negative margins render traditional growth-based metrics like PEG or forward P/E entirely inapplicable to its current, highly distressed financial and operational state.
Applying growth-oriented valuation frameworks to a company with a shrinking top line and negative operating leverage obscures the reality of its financial distress. Instead of growth multiples, analysts should focus on the cash burn rate and the remaining runway, as these are the only metrics that accurately reflect the company's immediate survival risk.